ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "7781001d-68c5-4c62-b5ce-a333f5a6ad5e"}, "_deposit": {"id": "2011028", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2011028"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02011028", "sets": ["1642838338003", "1642838407795"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakanishi, Shotaro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Goya, Masato", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Tamaki, Mitsuyoshi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Oshiro, Takuma", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Saito, Seiichi", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186499011": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_1522650717957": "ja", "subitem_1522651041219": "\u00a9 The Author(s) 2021"}, {"subitem_1522650717957": "en", "subitem_1522651041219": "Creative Commons Attribution 4.0"}, {"subitem_1522650717957": "en", "subitem_1522650727486": "https://creativecommons.org/licenses/by/4.0/", "subitem_1522651041219": "https://creativecommons.org/licenses/by/4.0/"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "mHSPC"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Time to CRPC"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Prostate cancer"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "3-Month %PSA"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "Objective:To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.\\nResults:In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of\u2009\u2265\u20098 (p\u2009=\u20090.004), an extent of disease value (EOD) of\u2009\u2265\u20092 (p\u2009=\u20090.004), and a 3-month PSA level\u2009\u003e\u20091% of the pretreatment level (p\u2009=\u20090.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. A 3-month PSA level\u2009\u003e\u20091% of the pretreatment level was an independent predictor of OS (p\u2009=\u20090.004). Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level\u2009\u003e\u20091% of the pretreatment level correlated with a poor prognosis.", "subitem_description_type": "Other"}, {"subitem_description": "\u8ad6\u6587", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "en", "subitem_1522300316516": "Springer Nature"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "eng"}]}, "item_1617186783814": {"attribute_name": "Identifier", "attribute_value_mlt": [{"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/20.500.12000/49968"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "1756-0500"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "en", "subitem_1522650091861": "BMC Research Notes"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueNumber": "1", "bibliographicVolumeNumber": "14"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "VoR", "subitem_1600292170262": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_1617353299429": {"attribute_name": "Relation", "attribute_value_mlt": [{"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "https://doi.org/10.1186/s13104-021-05641-5"}}, {"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "https://doi.org/10.1186/s13104-021-05641-5"}}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "Nakanishi2021_Article_Three-monthEarlyChangeInProsta.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2011028/files/Nakanishi2021_Article_Three-monthEarlyChangeInProsta.pdf"}, "version_id": "a100f1dc-b8c7-4c8e-a08f-30bb0d2bd5f4"}]}, "item_title": "Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer", "item_type_id": "15", "owner": "1", "path": ["1642838338003", "1642838407795"], "permalink_uri": "http://hdl.handle.net/20.500.12000/49968", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2021-11-09"}, "publish_date": "2021-11-09", "publish_status": "0", "recid": "2011028", "relation": {}, "relation_version_is_last": true, "title": ["Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. その他
  1. 部局別インデックス
  2. 医学部

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

http://hdl.handle.net/20.500.12000/49968
http://hdl.handle.net/20.500.12000/49968
30f75fb3-f12c-4d26-ac2d-807be793d684
名前 / ファイル ライセンス アクション
Nakanishi2021_Article_Three-monthEarlyChangeInProsta.pdf Nakanishi2021_Article_Three-monthEarlyChangeInProsta.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2021-11-09
タイトル
タイトル Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer
言語 en
作成者 Nakanishi, Shotaro

× Nakanishi, Shotaro

en Nakanishi, Shotaro

Goya, Masato

× Goya, Masato

en Goya, Masato

Tamaki, Mitsuyoshi

× Tamaki, Mitsuyoshi

en Tamaki, Mitsuyoshi

Oshiro, Takuma

× Oshiro, Takuma

en Oshiro, Takuma

Saito, Seiichi

× Saito, Seiichi

en Saito, Seiichi

アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
言語 ja
権利情報 © The Author(s) 2021
主題
言語 en
主題Scheme Other
主題 mHSPC
言語 en
主題Scheme Other
主題 Time to CRPC
言語 en
主題Scheme Other
主題 Prostate cancer
言語 en
主題Scheme Other
主題 3-Month %PSA
内容記述
内容記述タイプ Other
内容記述 Objective:To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.\nResults:In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥ 8 (p = 0.004), an extent of disease value (EOD) of ≥ 2 (p = 0.004), and a 3-month PSA level > 1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. A 3-month PSA level > 1% of the pretreatment level was an independent predictor of OS (p = 0.004). Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level > 1% of the pretreatment level correlated with a poor prognosis.
内容記述タイプ Other
内容記述 論文
出版者
言語 en
出版者 Springer Nature
言語
言語 eng
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
識別子
識別子 http://hdl.handle.net/20.500.12000/49968
識別子タイプ HDL
関連情報
関連識別子
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s13104-021-05641-5
関連識別子
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s13104-021-05641-5
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1756-0500
収録物名
言語 en
収録物名 BMC Research Notes
書誌情報
巻 14, 号 1
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-01 05:35:58.143666
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON

確認


Powered by WEKO3


Powered by WEKO3